SAR445877 shows early immune-driven responses in heavily pretreated MSS colorectal cancer, including liver mets, with key dose-safety tradeoffs.
Aung Naing, MD, FACP
Advertisement
Articles by Aung Naing, MD, FACP
Aung Naing, MD, FACP, discusses potential immune-related adverse effects in oncology.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5